They found a significant increase in prescribing rates for both drug classes, with higher prescriptions for GLP-1RAs in patients with obesity and for SGLT2i in patients with cardiovascular and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback